Hangzhou Doxy Biotech

Hangzhou Doxy Biotech is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative antibody-drug conjugates (ADCs) for oncology. The company has developed a proprietary ADC technology platform featuring unique linkers and potent payloads designed to improve the therapeutic window of cancer treatments. Its lead candidate, DXC007, is a TROP2-targeting ADC currently in Phase 2 clinical trials for various solid tumors. Doxy Biotech has established significant strategic collaborations, most notably a multi-target licensing agreement with Janssen Pharmaceuticals to leverage its ADC platform.